Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With Endometriosis
Status:
Terminated
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
Patients will undergo a standard history and physical examination detailing objective
clinical exam findings performed by one of the co-investigators. The research coordinator
will obtain baseline values for intensity of pain, quality of life, and coping strategies.
Baseline serum levels inflammatory markers will then be measured. Over the course of 12 weeks
Thalidomide will be titrated as tolerated to achieve a minimum of a 30% reduction of pain on
VAS from week 2.